Pharmaceutical companies in the EU should see conditional marketing authorization as a useful drug development planning tool, rather than as a "rescue option" to be used when they are unable to secure a full marketing authorization because they have not generated the required additional data, according to a senior European Commission official.
Speaking at Informa's EU Pharma Law Forum* in Brussels last week, Florian Schmidt of the pharmaceutical unit in the commission's...







